Change in Coronary Blood Flow After Percutaneous Coronary Intervention in Relation to Baseline Lesion Physiology Results of the JUSTIFY-PCI Study by Nijjer, SS et al.
Change in Coronary Blood Flow After Percutaneous Coronary 
Intervention in Relation to Baseline Lesion Physiology Results 
of the JUSTIFY-PCI Study
Sukhjinder S. Nijjer, MBChB, Ricardo Petraco, MD, Tim P. van de Hoef, MD, Sayan Sen, 
MBBS, PhD, Martijn A. van Lavieren, MSc, Rodney A. Foale, MD, Martijn Meuwissen, MD, 
PhD, Christopher Broyd, MBBS, Mauro Echavarria-Pinto, MD, Rasha Al-Lamee, MBBS, 
Nicolas Foin, PhD, Amarjit Sethi, MBBS, PhD, Iqbal S. Malik, MBBS, PhD, Ghada W. 
Mikhail, BSc, MD, Alun D. Hughes, MBBS, PhD, Jamil Mayet, MBChB, MD, MBA, Darrel P. 
Francis, MB BChir, MA, MD, Carlo Di Mario, MD, PhD, Javier Escaned, MD, PhD, Jan J. 
Piek, MD, PhD, and Justin E. Davies, MBBS, PhD1
1National Heart and Lung Institute, Imperial College London, London, United Kingdom (S.S.N., 
R.P., S.S., R.A.F., C.B., R.A.-L., N.F., A.S., I.S.M., G.W.M., A.D.H., J.M., D.P.F., C.D.M., J.E.D.); 
AMC Heart Centre, Amsterdam Medical Centre, Amsterdam, The Netherlands (T.P.v.d.H., 
M.A.v.L., J.J.P.); Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain (M.E.-P., 
J.E.); Department of Cardiology, Amphia Hospital, Breda, The Netherlands (M.M.); and 
Cardiovascular National Institute of Health Research Biomedical Research Unit, Royal Brompton 
Hospital, London, United Kingdom (C.D.M.)
Abstract
Background—Percutaneous coronary intervention (PCI) aims to increase coronary blood flow 
by relieving epicardial obstruction. However, no study has objectively confirmed this and assessed 
changes in flow over different phases of the cardiac cycle. We quantified the change in resting and 
hyperemic flow velocity after PCI in stenoses defined physiologically by fractional flow reserve 
and other parameters.
Methods and Results—Seventy-five stenoses (67 patients) underwent paired flow velocity 
assessment before and after PCI. Flow velocity was measured over the whole cardiac cycle and the 
wave-free period. Mean fractional flow reserve was 0.68±0.02. Pre-PCI, hyperemic flow velocity 
is diminished in stenoses classed as physiologically significant compared with those classed 
nonsignificant (P<0.001). In significant stenoses, flow velocity over the resting wave-free period 
and hyperemic flow velocity did not differ statistically. After PCI, resting flow velocity over the 
wave-free period increased little (5.6±1.6 cm/s) and significantly less than hyperemic flow 
velocity (21.2±3 cm/s; P<0.01). The greatest increase in hyperemic flow velocity was observed 
when treating stenoses below physiological cut points; treating stenoses with fractional flow 
reserve ≤0.80 gained Δ28.5±3.8 cm/s, whereas those fractional flow reserve >0.80 had a 
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significantly smaller gain (Δ4.6±2.3 cm/s; P<0.001). The change in pressure-only physiological 
indices demonstrated a curvilinear relationship to the change in hyperemic flow velocity but was 
flat for resting flow velocity.
Conclusions—Pre-PCI physiology is strongly associated with post-PCI increase in hyperemic 
coronary flow velocity. Hyperemic flow velocity increases 6-fold more when stenoses classed as 
physiologically significant undergo PCI than when nonsignificant stenoses are treated. Resting 
flow velocity measured over the wave-free period changes at least 4-fold less than hyperemic flow 
velocity after PCI.
Keywords
angioplasty; blood flow velocity; percutaneous coronary intervention
The purpose of percutaneous coronary intervention (PCI) is to relieve epicardial stenoses 
and thereby increase coronary flow ostensibly to relieve symptoms of angina. However, 
some studies suggest that PCI offers little clinical benefit over medical therapy,1 whereas 
others show that when PCI is guided by markers of physiological severity such as fractional 
flow reserve (FFR) outcomes can be improved.2–4 Because physiological parameters offer 
additional information about ischemia over angiographic assessment,5 the disparity in 
findings and improved outcome by application of physiology is likely because of improved 
differentiation of lesions into those with the highest likelihood of ischemia, and deferring 
those with lowest likelihood of ischemia.6 However, the uptake of physiology before PCI 
remains low.7 Even in centers with high-volume use, clinicians may choose to stent vessels 
in which physiological parameters, such as FFR, are above their thresholds (for example, 
FFR>0.80).7 Furthermore, it remains unconfirmed whether coronary physiological 
parameters identify stenoses, which will demonstrate an improvement in coronary flow and 
whether the increase in flow after PCI is predicted by physiological parameters.
In addition, new resting measures of stenosis severity have been proposed, such as the basal 
stenosis resistance (BSR) index and the instantaneous wave-free ratio (iFR). Although 
intracoronary pressure alone is known to increase after intervention,8 it is unclear how 
resting flow velocity, either over the whole cycle or the wave-free period, relates to each or 
behaves after intervention. Furthermore, because most application of physiology in clinical 
practice has been focused on pressure-only methodology, the precise relationship between 
pressure and flow velocity after PCI must be determined.
To investigate these issues, we assessed the change in both hyperemic and resting flow 
velocity after coronary intervention to a wide spectrum of stenoses in patients referred for 
PCI as a part of the Joined Coronary Pressure and Flow Analysis to Determine Diagnostic 
Characteristics of Basal and Hyperemic Indices of Functional Lesion Severity (JUSTIFY) 
study.9 Stenoses were treated according to anatomic and clinical information, and the 
change in flow velocity after PCI was assessed in relation to the physiological significance 
of the stenoses before PCI. Stenoses were defined physiologically by the reference standard 
pressure-only index (FFR). Further assessment was performed in relation to other 
physiological indices available in the catheter laboratory. Specifically, we sought to assess 
what increase in flow velocity should be expected for a change in a pressure index.
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Methods
Study Population
The JUSTIFY family of studies incorporate pressure and flow velocity data collected 
prospectively for research purposes from patients scheduled for elective percutaneous 
coronary angioplasty at the Amsterdam Medical Centre, the Netherlands, and Imperial 
College London, United Kingdom.9 The purpose of the JUSTIFY studies is to better 
understand the relationship between different indices of coronary stenosis. In this analysis, 
only cases using a single Combowire to acquire simultaneous pressure and flow velocity 
data before and after angioplasty were assessed. In total, 75 stenoses underwent PCI.
Patients with significant valvular disease or previous coronary artery bypass grafts were not 
included in this study. The local ethical review boards approved the respective study 
protocols, and all subjects gave written informed consent.
Study Protocol: Coronary Catheterization
Coronary angiography and pressure-flow velocity assessments of coronary stenoses were 
performed using conventional approaches via the femoral artery. Intracoronary nitrates (300 
µg) were administered in all cases before the introduction of coronary wires. Combined 
pressure and flow velocity wires (Combowire XT; Volcano Corporation, San Diego, CA) 
were normalized at the coronary ostia before every pressure recording. Measurements were 
made in the proximal vessel and distal to the stenosis. Adenosine was administered by 
central femoral vein in 43 stenoses (140 µg/kg per minute) and by intracoronary bolus in 32 
stenoses (60 µg). The dose of intracoronary adenosine exceeds the dose of adenosine 
originally validated for use in man (20–40 µg).10 The same dose was used before and after 
intervention. Coronary intervention was performed at the operators discretion based on usual 
clinical care, including angiographic and noninvasive findings. For postangioplasty 
measurements, all stents were optimized with postdilation where angiographically indicated 
before further assessment with pressure wire. Repeated measurements after angioplasty were 
performed at the same coronary location as preangioplasty.
Hemodynamic Recordings
The ECG, pressures, and flow velocity signals were directly extracted from the digital 
archive of the device console (ComboMap; Volcano Corporation). At the end of each 
recording the pressure sensor was returned to the catheter tip to ensure there was no pressure 
drift. Where drift was identified the measurements were repeated. An adequate flow velocity 
envelope was obtained in all patients permitting the calculation of flow-based indices. Data 
were analyzed off-line, using a custom software package designed with Matlab (Mathworks, 
Inc, Natick, MA).
Calculation of Pressure-Only Indices
iFR was calculated as a ratio of the distal coronary pressure:proximal coronary pressure at 
rest, using automated algorithms acting over the diastolic wave-free period as previously 
described in Adenosine Vasodilator Independent Stenosis Evaluation Study (ADVISE)11 
and validated in the Multicenter Core Laboratory Comparison of the Instantaneous Wave-
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Free Ratio and Resting Pd/Pa With Fractional Flow Reserve (RESOLVE).12 iFR is 
measured using intracoronary pressure-only, at baseline, without adenosine administration 
(Figure 1); its clinical cut point is 0.90 and has an ischemic cut point of 0.86.13 FFR 
measurements were performed using a standard technique,14 using the ratio of distal 
coronary pressure:proximal pressure during stable hyperemia; the clinical cut point is 0.80 
and has an ischemic cut point of 0.75.15
Calculation of Flow Velocity–Based Indices
Lesions were categorized by coronary flow reserve (CFR), calculated by the ratio of whole 
cycle resting flow velocity:hyperemic flow velocity16; values below 2 and 1.7 have been 
considered abnormal previously, and both thresholds were tested. The hyperemic stenosis 
resistance was calculated using the hyperemic transtenotic gradient indexed by the 
hyperemic flow velocity; values >0.80 mm Hg/cm s are abnormal.17 The BSR was similarly 
calculated but uses resting transtenotic gradient and resting flow velocity; values >0.66 mm 
Hg/cm s are abnormal.18
Equations for the intracoronary indices are as follows:
where Pa is the mean aortic pressure and Pd is the mean intracoronary pressure distal to 
stenosis
Calculation of Flow Velocity Over Different Windows
Flow velocity was assessed at rest over entire cardiac cycle (Rest Flowwhole cycle; Figure 1) 
and over the specific diastolic wave-free period during which iFR is calculated (Rest 
Flowwave-free period). Flow velocity was also assessed during adenosine-mediated hyperemia 
over the whole cardiac cycle (Hyperemic Flowwhole cycle) and the wave-free period 
(Hyperemic Flowwave free period). Flow velocity is reported for the whole group or FFR strata 
as mean±SE. In addition, it is reported as a ratio of flow velocity before and after PCI: for 
example, a prepost hyperemic flow velocity ratio of 1 would suggest no increase in flow 
velocity after PCI, whereas a ratio of 2 would suggest flow velocity had doubled.
Microvascular resistance was calculated before and after PCI according to the following 
equations (where flow indicates flow velocity [cm/s] and Pd indicates distal coronary 
pressure [mm Hg]).
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Microvascular resistance was used to estimate the presence of PCI-related 
microembolization which can affect post-PCI measurements. Because microembolization 
would prevent the microcirculation from responding to adenosine, the degree of 
embolization can be quantified by measuring the capacity of adenosine to reduce 
microvascular resistance (vasodilator reserve) post PCI. This was compared with the 
reduction in resistance offered by adenosine in stenoses with an FFR>0.80 pre-PCI because 
physiologically nonflow limiting stenoses are the most responsive to adenosine. In addition, 
CFR was measured post PCI to provide an additional manner to assess for the impact of 
embolization.
Data Analysis
Data are expressed as mean±SEM, unless otherwise stated. Patient demographics are 
presented as counts and percentages where appropriate. Correlations were assessed by 
Pearson correlation coefficient. Linear regression analysis was used to determine the 
coefficient of determination (R2) between quantitative variables. Regression analysis was 
used with polynomial best-fit curves to determine the relationship between quantitative 
variables. Relationships were determined to be linear or curvilinear based on appearance. 
Independent data were compared using Student t test and Mann–Whitney U test. Where data 
was paired, for example, before and after PCI, paired t tests were used. Comparisons of 
means between multiple groups were performed using ANOVA with Bonferroni, Sidak, and 
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Scheffe corrections for multiple testing; this was followed by pairwise analysis using the 
Tukey HSD test. Repeated measures correction was applied where appropriate. For all 
analyses, a value of P<0.05 was considered significant. Statistical analysis was performed 
using Matlab (Mathworks, Inc) and STATA version 11 (StataCorp, College Station, TX).
Results
Patient Characteristics
Measurements were made before and after coronary PCI in 67 patients (75 stenoses; 76% 
men; 62±9 years old). Demographics are shown in Table 1. Physiological parameters before 
and after PCI are shown in Table 2. The mean FFR pre-PCI was 0.68±0.02, which was 
comparable with Fractional Flow Reserve Guided Percutaneous Coronary Intervention Plus 
Optimal Medical (OMT) Treatment Verses OMT (FAME-2).4 The mean stenosis diameter 
was 56±1.3% by quantitative coronary angiography. Mean arterial pressure had only a 
limited relationship with flow velocity; this was true of flow velocity measurements made at 
rest and hyperemia and also true before and after PCI (R2 for all comparisons were <0.04).
Assessment of Coronary Flow Velocity Before PCI
Mean flow velocities at rest and during hyperemia were assessed (Figure 1) and assessed in 
relation to physiological parameters typically used to categorize stenoses as significant or 
not (Table 2). In all cases, regardless of the physiological parameter used to stratify the study 
population, by restricting the flow velocity measurement to the wave-free period (Resting 
Flowwave free period) elicited flow velocities that were significantly higher than those 
measured over the whole cardiac cycle at rest (Resting Flowwhole cycle). Hyperemic 
Flowwhole cycle was not different from Rest Flowwave free period in stenoses classed as 
physiologically significant by any of the parameters and cut points assessed (Table 2), but 
was greater when stenoses were classed as nonsignificant. Measuring flow velocity only 
during the wave-free period under conditions of hyperemia elicited significantly greater flow 
velocities than over the whole-cycle (P<0.001).
Change in Hyperemic Flow Velocity After Intervention
After PCI, the mean Hyperemic Flowwhole cycle across all stenoses rose significantly to 
51.0±2.87 cm/s. Stratification by FFR demonstrated that when stenoses had pre-PCI FFR 
values >0.80, Hyperemic Flowwhole cycle velocity increased by 4.6±2.3 cm/s; this was 
significantly less than when FFR values ≤0.80 (28.5±3.8 cm/s; P<0.001; Figure 2). 
Expressed as a ratio of flow velocity pre:post PCI, a similar finding was noted (FFR ≤0.80, 
pre:post flow velocity ratio of 2.83±0.0.29 versus 1.17±0.08; P<0.001). The behavior of 
hyperemic flow velocity over the wave-free period was similar to the whole cycle. 
Stratification by the other physiological parameters elicited a similar relationship (Figure 3).
Stenoses with an FFR 0.71 to 0.80 had a small but statistically nonsignificant increase in 
hyperemic flow velocity (Δ11.2±7.1 cm/s; P=0.14). Much larger increases in flow velocity 
were observed for stenoses with FFR 0.61 to 0.70 (Δ18.0±3.2 cm/s; P=0.007) and 
FFR≤0.60, Δ40.8±4.6 cm/s; P<0.001; Figure 2).
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Change in Resting Flow Velocity After Intervention
The change in resting flow velocity measured over the wave-free period was assessed 
(Figure 2A and 2B). In stenoses with FFR>0.80 before PCI, no significant increase in flow 
velocity was observed (0.3±2.4 cm/s; P=0.90). Similar small changes were noted for 
stenoses with FFRs of 0.6 to 0.70 and 0.70 to 0.80 (Figure 2A). Only when stenoses had 
FFR values of ≤0.60 was a significant increase in Rest Flowwave free period observed 
(13.7±2.2 cm/s); this was 3-fold smaller than the change in hyperemic flow velocity for this 
range. In all cases, when the pre-PCI FFR was <0.80, the change in hyperemic flow velocity 
after PCI was significantly greater than observed at rest (Figure 2B; P<0.01 for all).
Using Pressure Indices to Predicting the Change in Flow Velocity Before PCI
All the physiological parameters demonstrated significant increases after PCI (Table 3). The 
change in hyperemic flow velocity after PCI had a curvilinear relationship with both pre-PCI 
FFR and iFR values (Figure 4). Plotting the change in either pressure index with the change 
in flow velocity (Figure 5) shows that over the typical range of improvement in the index 
seen in clinical practice (≈0.20), then hyperemic flow velocity is likely to double while 
resting flow velocity had little rise. For larger changes in either index, then the increase 
hyperemic flow rises exponentially while resting flow shows significant rises only when 
increments in pressure are large.
Change in Microvascular Resistance After Intervention
To assess the impact of microembolization on the post-PCI measurements, the gain in 
resistance reduction offered by hyperemia over the whole cycle and the wave-free period at 
rest was compared with the resting whole cycle (Figure 6, top). A significant reduction in the 
vasodilator reserve would suggest embolization. Hyperemic vasodilator reserve rose after 
PCI (48±3%–61±2%; P<0.001), and there was no difference between post-PCI vasodilator 
reserve and that observed in stenoses with pre-PCI FFR values >0.80 (61±2% versus 
58±3%; P=0.44), suggesting that there was no important embolization. This was confirmed 
by measuring CFR, which significantly improved across all strata of FFR-positive stenoses 
(Figure 6, bottom) and had no significant relationship with either pre- or post-PCI FFR 
values (all P=ns). Under resting conditions, the wave-free period offered a consistent 
reduction in resistance across all stenoses (33±01%), and there was no difference per strata 
when pre-PCI FFR was >0.60. In the most significant stenoses (FFR≤0.60), pre-PCI, the 
wave-free period offered a greater reduction in resistance than those with FFR>0.60 
(P<0.001). It is likely severe stenoses are maximally vasodilated at rest to maintain resting 
flow. In this strata alone, post-PCI resting resistance is lower than before PCI (P<0.001); 
however, the value is numerically consistent with that of other strata. Because vasodilator 
reserve is maintained in these stenoses (as shown by the adenosine response post-PCI in this 
strata), this does not suggest embolization, rather a relative physiological vasoconstriction in 
response to the increased resting flow observed in these stenoses after the removal of a flow-
limiting stenosis.
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Discussion
In this study, we have demonstrated that (1) physiological severity of the lesion predicts the 
likelihood of coronary flow velocity increasing after coronary intervention, (2) hyperemic 
flow velocity changes most after PCI, whereas resting flow velocity changes little. We also 
find that the increase in hyperemic flow velocity is similar regardless of the physiological 
parameter used to dichotomize stenoses. In addition, we have determined a model for 
estimating the change in flow velocity after a change in pressure index.
Pressure-only indices are known to improve after intervention to a stenosis8,19 but because 
they use pressure as a surrogate estimate of flow, the increase in distal pressure could reflect 
other changes caused by PCI, such as microembolization or epicardial vessel spasm. Flow 
velocity is also known to change, but previous reports were limited by categorizing stenoses 
based on visual estimation of severity.20,21 In this study, we report the change in flow 
velocity according to pre-PCI physiological parameters, which overcomes the considerable 
limitations of visual or anatomic definitions of lesion severity. Furthermore, because the 
microvasculature continued to respond to adenosine after PCI in a manner similar to 
physiologically unobstructed vessels before PCI, then any impact of microembolization on 
the flow velocity post-PCI was small.
Hyperemic Flow Velocity Before and After Intervention
Hyperemic flow considers all the potential blood flow that can occur when the tightly 
controlled myocardial-coronary autoregulatory processes are uncoupled by the use of a 
vasodilator. Hyperemic flow velocity declines in presence of stenoses occupying 50% of the 
vessel lumen.22,23 Conceptually, if a stenosis can be reduced to <50%, one would expect an 
improvement in hyperemic flow velocity, to similar levels seen in vessels when there is no 
stenosis. Because the angiographic appearance of stenoses can reflect poorly its importance, 
we chose to classify stenoses by FFR, which is a familiar and easily understood alternative. 
Furthermore, the concept of FFR should lead to predictable increases in coronary flow 
velocity after PCI.
Before PCI, in physiologically significant stenoses, hyperemic flow velocity measured over 
the whole cardiac cycle was greater than resting flow velocity measured over the whole 
cycle. However, it was not significantly different from resting flow velocity measured over 
the wave-free period. This demonstrates that constraining flow analyses to a period in 
diastole provides a higher flow velocities than measurable over the whole cardiac cycle and 
also that in significant stenoses there is little difference between what is calculable at rest 
and hyperemia. This is in keeping with the Classification Accuracy of Pressure-Only Ratios 
Against Indices Using Flow Study (CLARIFY) study that showed ischemic stenoses 
demonstrated comparable microvascular resistance both over the resting wave-free period 
and during whole-cycle hyperemia.13
A higher flow velocity in the pre-PCI setting is pertinent for the diagnostic sensitivity of 
pressure-only indices, which rely on the highest transtenotic gradient possible to sufficiently 
distinguish between mild, moderate, and severe stenoses.22 FFR uses exogenous hyperemia 
to increase flow velocity to a level, where it is more easy to distinguish stenosis severities 
Nijjer et al. Page 8
Circ Cardiovasc Interv. Author manuscript; available in PMC 2016 July 13.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
than possible by Pd/Pa at rest. For iFR, a resting pressure index measured only over the 
wave-free period, the higher velocities would mean greater stenosis discrimination at rest 
than a whole cycle resting index.
Because the resting wave-free flow velocity and hyperemic whole cycle flow velocity were 
statistically similar for stenoses classed as significant whether by FFR, iFR, BSR, hyperemic 
stenosis resistance, or CFR, then it likely that this finding is valid by whatever means is used 
to stratify stenoses.
The findings of hyperemic stenosis resistance and BSR are pertinent because these 
parameters index transtenotic gradients by flow velocity and thereby limit possible false-
positives that may occur with pressure-only indices.9,24,25 Although rarely considered and 
not previously detected without simultaneous flow velocity measurement, false-positive 
pressure-only indices will occur when flow velocity can increase significantly during 
hyperemia (which by definition, cannot be flow limiting) to generate an apparently 
important pressure gradient.26 Most importantly, these lesions carry the same prognosis >10 
years as those which are negative using FFR guidance.25
After PCI, hyperemic flow velocities were broadly similar to the values seen in the presence 
of stenoses labeled as physiologically nonsignificant (either by FFR>0.80 or any of the other 
indices; Figure 2A). That is, stenoses with FFR>0.80 had a mean hyperemic flow velocity of 
41±5 cm/s; after PCI, the entire cohort had a flow velocity of 53±3 cm/s, whereas those with 
FFR 0.61 to 0.70 had a mean of 47±5 cm/s and those with FFR 0.71 to 0.80 had a mean 
42±6 cm/s. All of these values are statistically similar, suggesting that this value of flow 
velocity should be expected, on average, after intervention. The greatest increment in 
hyperemic flow velocity was seen in stenoses when FFR≤0.70 pre-PCI (Figure 2B), which is 
similar to the FFR value that is most closely related to ischemia on noninvasive testing 
(FFR=0.75).15 This value is also remarkably similar to the FFR value (0.67) determined to 
have prognostic value on a large meta-regression.27
Smaller, less significant increments in hyperemic flow velocity are noted for higher FFR 
values, with little increase in stenoses typically considered nonischemic (FFR>0.80). These 
findings are in keeping with the basic tenets of FFR and likely account for the findings of 
DEFER and FAME—concentrating PCI to stenoses most likely to increase flow should lead 
to more favorable outcomes. At present, it remains unclear what degree of flow velocity 
increase is required to achieve symptomatic benefit or reduce clinical events.
Other indices of stenoses significance also predicted similar increases in hyperemic flow 
velocity after PCI: when stratified by CFR, hyperemic stenosis resistance, BSR, and iFR, the 
change in flow velocity was always significantly higher when stenoses were classed as 
significant by the given parameter than when classed as nonsignificant (Figure 3).
Higher values of post-PCI flow velocity may be achievable in animal models, which use 
external constrictors to mimic a lesion; typically in those models there can be a lack of 
generalized atheroma, and a lack of microcirculatory disease. In this study, in humans with 
coronary artery disease, the post-PCI flow velocity will be modulated by many factors 
including atheroma and the completeness of PCI which will differ from the release of an 
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external constrictor. The values of post-PCI hyperemic flow velocity are consistent with 
those measured in unobstructed vessels in humans.10,28
Resting Flow Velocity Changes Little After Coronary Intervention
Previous studies assessing Doppler flow velocity suggested that post-PCI CFR may be 
underestimated because of a rise in resting flow velocity.29 Others showed modest change in 
resting flow velocity immediately after balloon angioplasty.30 In this modern cohort, 
undergoing PCI as per current practice, resting flow velocity only changed significantly after 
stent placement and optimization in highly significant lesions. The maintenance of resting 
flow velocity at a steady figure despite the removal of a stenosis likely demonstrates in vivo 
coronary autoregulation. Only profoundly significant stenoses (with FFR<0.60 or iFR<0.50) 
demonstrated significant change in resting flow velocity. Nonetheless, mean post-PCI CFR 
values exceed normal levels and increased significantly for all stenoses with pre-PCI 
FFR<0.80 (Figure 6, bottom). Note that CFR has been criticized because a value of 3 may 
be half of normal if a given vessel has a CFR of 6.31 However, although normal 
unobstructed vessels in young patients or animals may have exceptionally high CFRs, in this 
cohort of patients with coronary disease requiring PCI, such high CFRs are not observed. It 
is possible diffuse epicardial resistance limited exceedingly high post-PCI CFRs.
Predicting the Change in Flow Velocity Using Pressure-Only Indices
Both the pre-PCI FFR and the iFR values significantly predict the change in hyperemic flow 
velocity significantly, in a curvilinear fashion. Both indices had similar predictive power, 
despite the difference in calculation (iFR measured at rest and FFR measured during 
hyperemia). Similarly, the δ of the pressure index demonstrated a complex curvilinear 
relationship with the change in flow velocity. However, for both iFR and FFR, change in the 
index over the typical range seen clinically (0.22 for FFR and 0.20 for iFR8) lead to little 
change in resting flow velocity and a more linear increase in hyperemic flow velocity after 
PCI. This means for typical stenoses showing average changes in either pressure index, 
interventionalists can be reassured that increments in the pressure ratio directly reflect 
increments in flow velocity increase.
Practical Clinical Implications
Our findings strongly support the use of physiological techniques to detect lesions which are 
both likely ischemia producing, but also likely to benefit from PCI, and provide mechanistic 
support to the established clinical trials (FAME, FAME-2).3,4 By reducing the number of 
stents being implanted, the likelihood of procedural complications is reduced. This is 
particularly emphasized whenever compared with an approach that attempts to stent all 
stenoses whereby the theoretical risks of stenting apply to each one placed while the 
potential benefit of flow increase may be confined to a few. By focusing on treating stenoses 
most likely to lead to a measurable flow increase, PCI may be more likely to improve 
symptoms and potentially reduce cardiac events.
The relative little change in resting flow velocity may have important clinical applications 
for the interrogation of tandem lesions or in diffuse disease, particularly for planning 
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intervention, where the greater change in hyperemic flow velocity can limit practical 
prediction of the impact of stenting a given stenosis when multiple stenoses are present.32
Limitations
This study is comparatively smaller than pressure-only studies that assess change in pressure 
before and after PCI. However, it is one of the largest reported using simultaneous pressure–
flow velocity wire before and after PCI in the modern era.
In this data set, assessments were paired, and the doses of adenosine used post-PCI 
measurements were consistent with pre-PCI doses allowing direct comparisons of FFR 
values and hyperemic flow velocities. Those stenoses assessed by intracoronary adenosine 
were done so using a conservative dose that although exceeding original validation work, 
has been superseded in clinical practice (doses 100–150 µg are now favored). Higher doses 
of adenosine may elicit higher flow velocities, but this is dependent on the true severity of 
the underlying stenosis: truly flow-limiting stenoses are likely to have little gain in flow 
velocity regardless of the dose (eg, stenoses with FFR≤0.60), whereas those not truly flow 
limiting will have a greater increase in flow velocity (eg, those stenoses with FFR>0.80). 
Higher doses may also make FFR values become marginally lower,33 with greatest impact 
on stenoses with borderline FFR values most (those just >0.80 may be reclassified as just 
<0.80). This may mean that the marginal increase in hyperemic flow velocity observed for 
stenoses with pre-PCI FFR values of 0.70 to 0.80 may be even smaller than shown here. For 
the change in resting flow velocity, no difference in results is expected because 
measurements are made without adenosine and change in resting flow was only observed for 
stenoses with pre-PCI FFR≤0.60.
Physiologically nonsignificant stenoses demonstrated some improvement in flow velocity; 
on average, this was a small amount compared with when stenoses were significant. Because 
it is still unclear what degree of flow velocity increase will improve symptoms or produce 
prognostic benefit, we cannot be sure whether such increases are worthwhile.
Coronary flow velocity measurements in truly significant stenoses can be difficult to 
perform as velocities are diminished. The 2 centers involved in stenosis assessment have >10 
years of experience each in performing these measurements meaning the an adequate wave-
form for phasic analysis was possible.
Flow velocity measurements were taken once operators had completed PCI. It is unclear 
whether flow velocity would continue to improve at a later date.
Wedge pressure recordings to estimate the impact of collateral flow were not routinely 
performed in this study. Visible collaterals were avoided during this study, but nonvisible 
vessels may have been present in those with significant FFR values. Because collaterals are 
expected to close on removal of the stenosis, it is not expected that they would significantly 
alter the findings. Wedge occlusion can also be used to correct hyperemic resistance 
measurements, which may otherwise be overestimated in severe stenoses (FFR<0.60). In 
this study, because vasodilator response was used only to exclude a significant impact of 
embolization, the overall interpretation is not altered.
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Volumetric absolute coronary flow was not measured because the potential error, imposed 
by the technical limitations of measuring vessel size, is large. Although coronary size will 
change around the lesion, flow velocity measurements were made at the same location distal 
to the region of interest, in an area that did not change size. Thereby the changes in flow 
velocity are likely to equate to changes in absolute flow.
This study was performed in humans with coronary artery disease referred to the catheter 
laboratory for assessment and treatment. As such, the results are applicable to other patients. 
The results may differ from animal studies, however, particularly in young animals with 
distensible microcirculation and external constrictors used for simulating a stenosis 
simulation. In these models, removal of a stenosis may manifest even higher flow velocities 
than seen in humans although the clinical relevance is unclear.
Conclusions
Physiological assessment tools can strongly predict the likely increase in coronary flow 
velocity after PCI. This change is most marked in physiologically more severe lesions where 
the difference between resting and hyperemic flow velocity measurements is small.
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What is Known
Fractional flow reserve is a pressure-based index, which in animal models of stenoses has 
a close relationship with flow velocity. Patients undergoing stenting as directed by 
coronary physiological parameters, such as fractional flow reserve, have improved 
outcomes compared with less discriminate stenting based on angiography.
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What the Study Adds
Hyperemic flow velocity improves significantly after removal of a coronary stenosis in 
humans. Stenoses classified as physiologically important demonstrate the greatest gain in 
flow velocity, regardless of the index chosen for stratification. The incremental gain in 
hyperemic flow velocity is related to the pre–percutaneous coronary intervention 
physiological severity with the greatest gain seen in the strata in which fractional flow 
reserve was shown to predict hard outcomes in a large metaregression. Resting coronary 
flow velocity, over the wave-free period, shows only small changes after stenting. 
Coronary intervention in stable disease does not significantly alter microvascular 
responsiveness to adenosine or the wave-free period.
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Figure 1. 
Flow velocity across a stenosis before percutaneous coronary intervention (PCI). 
Simultaneous trans-stenotic pressure and flow velocity measurements permit assessment of 
hemodynamic change before and after PCI. Flow velocity can be measured during 
adenosine-mediated hyperemia over the entire cardiac cycle (Hyperemic Flowwhole cycle). It 
can also be measured under basal conditions, over the whole cardiac cycle (Rest 
Flowwhole cycle) or over the specific part in diastole known as the wave-free period (Rest 
Flowwave-free period).
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Figure 2. 
A, Paired mean flow velocity shown before and after percutaneous coronary intervention 
(PCI) measured during hyperemia (blue) and the wave-free period (red). Fractional flow 
reserve (FFR) ≤0.60 had 28 stenoses; FFR 0.61 to 0.70: 10 stenoses; FFR 0.71 to 0.80: 14 
stenoses; FFR >0.80: 23 stenoses. Hyperemic flow increases most for highly physiologically 
significant lesions (FFR≤0.70). Flow over the iFR-window is remarkably stable throughout 
all levels of lesion severity and changes little after PCI. Rest Flowwave-free period has little 
variability between FFR categories of stenosis severity. B, The change in flow velocity after 
PCI. Hyperemic Flowwhole cycle increases significantly more than the increases in Rest 
Flowwave-free period for every FFR category of stenosis severity. *P≤0.01.
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Figure 3. 
The change in hyperemic flow after percutaneous coronary intervention (PCI) according to 
different pre-PCI indices. Coronary flow reserve (CFR), fractional flow reserve (FFR), 
instantaneous wave-free ratio measured at rest (iFR), or during adenosine-mediated 
hyperemia (iFRa), basal stenosis resistance (BSR), and hyperemic stenosis resistance (HSR) 
were used to classify stenoses as physiologically significant (⊕) or physiologically 
nonsignificant (Ө) according to their respective cut points, as described in the Methods 
section of this article. The change in hyperemic flow velocity after PCI (top) was 
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significantly higher when stenoses were physiologically significant (⊕) than when 
nonsignificant (Ө), regardless of the index used. *P=0.01, **P<0.001. Bottom, The change 
in resting wave-free period flow using the same annotation.
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Figure 4. 
The relationship between pre-percutaneous coronary intervention (PCI) pressure-only 
physiological indices and the increase in hyperemic flow velocity after PCI. Hyperemic flow 
increases significantly following PCI. A ratio of pre-PCI and post-PCI hyperemic flow 
velocity was plotted using a third-order polynomial against the pre-PCI fractional flow 
reserve (FFR) value. Ratios above 1 suggest an increase in flow velocity, whereas those 
below 1 suggest a fall. iFR indicates instantaneous wave-free ratio.
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Figure 5. 
Estimating the change in hyperemic flow velocity based on the δ or change in pressure-only 
index after percutaneous coronary intervention (PCI). Pressure-only indices increase after 
PCI and demonstrate a curvilinear relationship with the change in resting and hyperemic 
flow velocity. For a change in instantaneous wave-free ratio (iFR), the change in wave-free 
flow velocity was predicted by the curve y=7.522x3−2.863x2+0.6754x+1.1943, whereas the 
change in hyperemic flow velocity was predicted by the curve y=18.96x3−11.94x2+5.6048x
+1.304. For fractional flow reserve (FFR), the change in resting wave-free flow velocity was 
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predicted by a curve y=20.7x3−9.1852x2+2.0422x+1.1019, whereas the change in 
hyperemic flow was y=17.175x3−0.1665x2−3.0192x+1.0898.
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Figure 6. 
Change in microvascular resistance and flow reserve after percutaneous coronary 
intervention (PCI). Top, The capacity for hyperemia and the wave-free period to reduce 
resistance compared with the resting whole cycle was compared before and after PCI as a 
marker of microembolization. Post PCI, the hyperemic effect was not significantly blunted, 
suggesting no impact of embolization. Bottom, This was confirmed by assessing the 
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capacity of coronary flow reserve (CFR) to increase after PCI. FFR indicates fractional flow 
reserve.
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Table 1
Patient Demographic Data for Patients From the JUSTIFY Study in Which Paired 
Assessments Before and After PCI Were Made
PCI Patients
n %
Patients 67
    Age, y 62± 9
    Men 50 74.6
    Hypertension 36 53.7
    Hyperlipidemia 56 83.6
    Current or ex-smoker 31 46.3
    Diabetes mellitus 19 28.4
    Chronic renal impairment 4 6.0
    Previous myocardial infarction 8 11.9
    Family history of CAD 29 43.3
    Impaired LV function EF<30% 1 1.5
    Stable angina 64 95.5
    Unstable angina 3 4.5
    Single-vessel disease 42 62.7
    Multivessel disease 25 37.3
Stenoses 75
    Coronary vessel
       Left anterior descending 44 58.7
       Circumflex 13 17.3
       Right coronary 18 24.0
    Lesion characteristics
       Lesion severity (QCA %) 61.4 ± 13.9
    Adenosine administration
       Central intravenous 43 57.3
       Intracoronary bolus 32 42.7
Values are n, mean±SD or n (%). CAD indicates coronary artery disease; EF, ejection fraction; JUSTIFY, Joined Coronary Pressure and Flow 
Analysis to Determine Diagnostic Characteristics of Basal and Hyperemic Indices of Functional Lesion Severity; LV, left ventricle; PCI, 
percutaneous coronary intervention; and QCA, quantitative coronary angiography.
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Table 2
Comparison of Flow Velocities Measured Either Over the Whole Cycle or the Diastolic 
Wave-Free Period, Either at Rest or During Hyperemia
Pre-PCI Flow Velocities, cm/s
Hyperemic Flowwfp Hyperemic Flowwhole cycle Rest Flowwfp Rest Flowwhole cycle Comparison
n Mean SEM Mean SEM Mean SEM Mean SEM
Hyperemic 
Flowwfp vs 
Hyperemic 
Flowwhole cycle
Hyperemic 
Flowwhole cycle 
vs Rest 
Flowwfp
Rest 
Flowwhole cycle 
vs Rest 
Flowwfp
Physiologically significant stenoses
FFR
≤0.75 44 27.4 2.4 23.6 2.1 21.8 1.9 16.8 1.4 <0.001 0.54 <0.001
≤0.8 52 29.4 2.3 25.0 2.0 22.2 1.7 17.2 1.3 <0.001 0.29 <0.001
iFR
≤0.86 42 27.7 2.3 23.6 2.1 23.0 1.9 17.8 1.4 <0.001 0.82 0.002
≤0.9 53 31.2 3.0 25.8 2.3 23.9 2.0 18.3 1.4 <0.001 0.55 <0.001
iFRa <0.66 47 27.9 2.3 23.8 2.0 22.0 1.8 17.0 1.4 <0.001 0.53 <0.001
HSR >0.80 45 25.0 1.7 21.2 1.5 19.0 1.3 14.9 1.1 <0.001 0.30 <0.001
BSR >0.66 38 23.3 1.6 19.6 1.5 19.0 1.5 14.8 1.2 <0.001 0.80 <0.001
CFR
<2.0 49 29.0 2.2 24.0 1.9 24.1 1.8 18.7 1.4 <0.001 0.97 <0.001
<1.7 41 29.2 2.6 24.3 2.2 25.8 2.1 19.9 1.5 <0.001 0.97 <0.001
Physiologically nonsignificant stenoses
FFR
>0.75 31 47.9* 4.6 37.5* 4.2 24.2 2.3 18.8 1.6 <0.001 0.001 <0.001
>0.8 23 50.5* 5.9 39.1* 5.4 24.3 2.8 18.8 1.7 <0.001 0.002 <0.001
iFR
>0.86 33 46.3* 4.6 37.7* 4.0 22.6 2.2 17.5 1.5 <0.001 0.002 <0.001
>0.9 22 47.0* 4.6 39.6* 5.0 20.1 1.2 16.2 0.9 <0.001 0.001 <0.001
iFRa >0.66 28 49.3* 5.0 40.0* 4.5 24.1 2.5 18.7 1.6 <0.001 0.003 <0.001
HSR <0.80 30 52.1* 4.7 42.8* 4.2 28.5 2.7 21.8 1.8 <0.001 0.006 <0.001
BSR <0.66 37 48.8* 4.1 40.4* 3.6 26.7 2.3 20.6 1.5 <0.001 0.002 <0.001
CFR
≥2.0 26 48.7* 5.6 40.8* 4.9 20.4 2.3 15.8 1.5 <0.001 <0.001 <0.001
≥1.7 34 43.9* 4.6 36.5* 4.0 19.2 1.9 14.9 1.2 <0.001 <0.001 <0.001
Flow velocities are compared according to physiological stenosis significance as determined by many different parameters. Where different 
thresholds have been proposed, both thresholds have been assessed. CFR indicates coronary flow reserve; FFR, fractional flow reserve; HSR, 
hyperemic stenosis resistance; iFR, instantaneous wave-free ratio; iFRa, adenosine-mediated hyperemia; PCI, percutaneous coronary intervention; 
and wfp, wave-free period.
*P<0.001 difference between flow for physiologically significant stenoses and nonsignificant stenoses for the given index.
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